Abstract:While rapid development and roll out of COVID-19 vaccines is necessary in a pandemic, the process limits the ability of clinical trials to assess longer-term vaccine efficacy. We leveraged COVID-19 surveillance data in the U.S. to evaluate vaccine efficacy in U.S. Government-funded COVID-19 vaccine efficacy trials with a three-step estimation process. First, we used a compartmental epidemiological model informed by county-level surveillance data, a "population model", to estimate SARS-CoV-2 incidence among the unvaccinated. Second, a "cohort model" was used to adjust the population SARS-CoV-2 incidence to the vaccine trial cohort, taking into account individual participant characteristics and the difference between SARS-CoV-2 infection and COVID-19 disease. Third, we fit a regression model estimating the offset between the cohort-model-based COVID-19 incidence in the unvaccinated with the placebo-group COVID-19 incidence in the trial during blinded follow-up. Counterfactual placebo COVID-19 incidence was estimated during open-label follow-up by adjusting the cohort-model-based incidence rate by the estimated offset. Vaccine efficacy during open-label follow-up was estimated by contrasting the vaccine group COVID-19 incidence with the counterfactual placebo COVID-19 incidence. We documented good performance of the methodology in a simulation study. We also applied the methodology to estimate vaccine efficacy for the two-dose AZD1222 COVID-19 vaccine using data from the phase 3 U.S. trial (ClinicalTrials.gov # NCT04516746). We estimated AZD1222 vaccine efficacy of 59.1% (95% uncertainty interval (UI): 40.4%–74.3%) in April, 2021 (mean 106 days post-second dose), which reduced to 35.7% (95% UI: 15.0%–51.7%) in July, 2021 (mean 198 days post-second-dose). We developed and evaluated a methodology for estimating longer-term vaccine efficacy. This methodology could be applied to estimating counterfactual placebo incidence for future placebo-controlled vaccine efficacy trials of emerging pathogens with early termination of blinded follow-up, to active-controlled or uncontrolled COVID-19 vaccine efficacy trials, and to other clinical endpoints influenced by vaccination.

Improving precision of vaccine efficacy evaluation using immune correlate data in time-to-event models

Elucidating vaccine efficacy using a correlate of protection, demographics, and logistic regression

Efficient nonparametric inference on the effects of stochastic interventions under two-phase sampling, with applications to vaccine efficacy trials

Estimating Waning of Vaccine Effectiveness: a Simulation Study

Comparing HIV Vaccine Immunogenicity across Trials with Different Populations and Study Designs

Increasing efficiency and reducing bias when assessing HPV vaccination efficacy by using non-targeted HPV strains

Distinguishing Immunologic and Behavioral Effects of Vaccination

Vaccine efficacy for binary post-infection outcomes under misclassification without monotonicity

Methods for the estimation of direct and indirect vaccination effects by combining data from individual‐ and cluster‐randomized trials

Distinguishing immunological and behavioral effects of vaccination

A Bayesian framework for estimating vaccine efficacy per infectious contact

Evaluation of Treatment Effect Modification by Biomarkers Measured Pre- and Post-randomization in the Presence of Non-monotone Missingness

Estimating COVID-19 Vaccine Efficacy via Dynamic Epidemiological Models–A Study of Ten Countries

Estimating vaccine efficacy during open-label follow-up of COVID-19 vaccine trials based on population-level surveillance data

Improved Methods for Vaccine Effectiveness Studies

A novel approach for estimating vaccine efficacy for infections with multiple outcomes: application to a COVID-19 vaccine trial

Post-randomization Biomarker Effect Modification in an HIV Vaccine Clinical Trial

Estimation and Hypothesis Testing of Strain-Specific Vaccine Efficacy with Missing Strain Types, with Applications to a COVID-19 Vaccine Trial

Variant Specific Treatment Effects with Applications in Vaccine Studies

Competing Heterogeneities in Vaccine Effectiveness Estimation

Assessment of Immune Correlates of Protection via Controlled Vaccine Efficacy and Controlled Risk